The first GITR-specific agonistic antibody to be developed was the anti-mouse DTA-1 antibody (6, 25), and its in vivo administration can overcome cancer tolerance and induce tumor rejection in several mouse tumor models (26–28). This evidence concerns the gene TNFRSF18 and neoplasm.